Home/Filings/4/0001179110-19-002371
4//SEC Filing

CHASE WILLIAM J 4

Accession 0001179110-19-002371

CIK 0001551152other

Filed

Feb 21, 7:00 PM ET

Accepted

Feb 22, 5:20 PM ET

Size

14.3 KB

Accession

0001179110-19-002371

Insider Transaction Report

Form 4
Period: 2019-02-21
CHASE WILLIAM J
EVP, Chief Financial Officer
Transactions
  • Award

    Common Stock, $0.01 par value

    2019-02-21+22,150127,013 total
  • Award

    Option (right to buy)

    2019-02-21+60,74760,747 total
    Exercise: $79.02From: 2020-02-21Exp: 2029-02-20Common Stock (60,747 underlying)
  • Award

    Common Stock, $0.01 par value

    2019-02-21+14,989157,947 total
  • Award

    Common Stock, $0.01 par value

    2019-02-21+15,945142,958 total
  • Award

    Common Stock, $0.01 par value

    2019-02-21+8,481166,428 total
Holdings
  • Common stock, $0.01 par value

    (indirect: By Spouse)
    501
Footnotes (6)
  • [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.
  • [F2]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.
  • [F3]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.
  • [F4]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.
  • [F5]The reporting person disclaims beneficial ownership of these securities.
  • [F6]Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,249 on February 21, 2020, 20,249 on February 21, 2021, and 20,249 on February 21, 2022.

Issuer

AbbVie Inc.

CIK 0001551152

Entity typeother

Related Parties

1
  • filerCIK 0001563572

Filing Metadata

Form type
4
Filed
Feb 21, 7:00 PM ET
Accepted
Feb 22, 5:20 PM ET
Size
14.3 KB